From: Systematic review of available evidence on 11 high-priced inpatient orphan drugs
Indication | Treatment | Prevalence (100,000 live births)* | Estimated annual costs / patient in € ** | Dutch budget impact in € ** | Year costs were assessed | Exceptional circumstances authorization |
---|---|---|---|---|---|---|
Acute Lymphoid Leukemia (ALL) in children | Clofarabine (Evoltra) | 8.1 | 54Â K | 0.7Â M | 2007 | Yes |
Cryopyrin Associated Periodic Syndromes (CAPS) | Canakinumab (Ilaris) | 0.10 *** | 66Â K | 2.6Â M | 2010 | Yes |
Chronic Lymphoid Leukemia (CLL) in patients refractory to fludarabine and alemzumab | Ofatumumab (Arzerra) | 30 | 39Â K | 1.0Â M | 2011 | No |
Fabry disease | Agalsidase α (Replagal) | 30 | 199 K | 3.2 M | 2009 | Yes |
Fabry disease | Agalsidase β (Fabrazyme) | 30 | 194 K | 5.7 M | 2009 | No |
Mucopolysaccharidosis I (MPSI) | Laronidase (Aldurazyme) | 1.3 | 300Â K | 7.5Â M | 2003 | Yes |
Mucopolysaccharidosis II (MPSII) | Idursulfase (Elaprase) | 0.6 | 600Â K | 9.6Â M | 2007 | Yes |
Mucopolysaccharidosis VI (MPSVI) | Galsulfase (Naglazyme) | 0.16 | 600Â K | 4.2Â M | 2007 | Yes |
Paroxysmal Nocturnal Hemoglobinuria (PNH) | Eculizumab (Soliris) | 0.8 | 358Â K | 10.6Â M ***** | 2008-2010 | No |
Pompe disease | Alglucosidase alfa (Myozyme) | 1.5 | 38Â K; 382Â K **** | 31.0Â M | 2007 | No |
Soft Tissue Sarcoma (STS) | Trabectedin (Yondelis) | 23.7 | 22Â K | 5.3Â M | 2010 | Yes |